• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期肝内胆管癌R0肝切除术后的条件无复发生存率:基于炎症-营养状态的竞争风险分析

The conditional recurrence-free survival after R0 hepatectomy for locally advanced intrahepatic cholangiocarcinoma: A competing risk analysis based on inflammation-nutritional status.

作者信息

Huang Guizhong, Xi Pu, Yao Zehui, Zhao Chongyu, Li Xiaohui, Lin Xiaojun

机构信息

Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.

出版信息

Heliyon. 2024 Jul 2;10(13):e33931. doi: 10.1016/j.heliyon.2024.e33931. eCollection 2024 Jul 15.

DOI:10.1016/j.heliyon.2024.e33931
PMID:39055818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11269833/
Abstract

BACKGROUND

Conditional survival analysis can serve as a dynamic prognostic metric, which helps to estimate the real-time survival probability over time. The present study conducted a conditional recurrence-free survival (CRFS) analysis for locally advanced intrahepatic cholangiocarcinoma (ICC) after R0 hepatectomy from an inflammatory-nutritional perspective using the competing risk method.

METHODS

We extracted the medical data of 164 locally advanced ICC patients after R0 resection from Sun Yat-sen University Cancer Center. The calculation formula of the CRFS rate is CRFS(y/x) = RFS(y + x)/RFS(x). Univariable and multivariable COX regression analysis and competing risk analysis were conducted to identify RFS indicators.

RESULTS

Considering death before recurrence as a competing risk factor, the conditional RFS rates every 6 months gradually increased over time. The 24-month RFS rate increased from 29.2 % to 49.9 %, 68.5 %, and 85.1 % given 6, 12, and 18-month already recurrence-free survival, respectively. Both in multivariate COX regression analysis and competing risk analysis, tumor diameter and number, lymph node metastasis, aggregate systemic inflammation index score (AISI), and albumin-bilirubin score (ALBI) all remained significant. For both AISI and ALBI variables, the CRFS rates in the low-value set were higher than those of the high-value set.

CONCLUSIONS

Conditional RFS rates of locally advanced ICC after R0 hepatectomy dynamically increased over time, which contributed to reducing survivors' psychological distress and facilitating personalized follow-up schedules. In addition, a person's inflammatory and nutritional status significantly impact the recurrence risk. Oncologists should consider the role of inflammation-nutritional status when making decisions for patients with locally advanced ICC.

摘要

背景

条件生存分析可作为一种动态预后指标,有助于估计随时间变化的实时生存概率。本研究从炎症 - 营养角度,采用竞争风险法对局部晚期肝内胆管癌(ICC)行R0肝切除术后进行无复发生存期(CRFS)分析。

方法

我们从中山大学肿瘤防治中心提取了164例局部晚期ICC患者R0切除后的医疗数据。CRFS率的计算公式为CRFS(y/x) = RFS(y + x)/RFS(x)。进行单变量和多变量COX回归分析以及竞争风险分析以确定RFS指标。

结果

将复发前死亡视为竞争风险因素,每6个月的条件RFS率随时间逐渐增加。在已无复发存活6、12和18个月的情况下,24个月的RFS率分别从29.2%增至49.9%、68.5%和85.1%。在多变量COX回归分析和竞争风险分析中,肿瘤直径和数量、淋巴结转移、全身炎症综合指数评分(AISI)以及白蛋白 - 胆红素评分(ALBI)均保持显著。对于AISI和ALBI变量,低值组的CRFS率高于高值组。

结论

局部晚期ICC行R0肝切除术后的条件RFS率随时间动态增加,这有助于减轻幸存者的心理困扰并促进个性化随访计划。此外,个体的炎症和营养状况对复发风险有显著影响。肿瘤学家在为局部晚期ICC患者做决策时应考虑炎症 - 营养状况的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/235f75988fa9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/fed56f4d1872/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/b89fbc22d279/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/235f75988fa9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/fed56f4d1872/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/b89fbc22d279/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/11269833/235f75988fa9/gr3.jpg

相似文献

1
The conditional recurrence-free survival after R0 hepatectomy for locally advanced intrahepatic cholangiocarcinoma: A competing risk analysis based on inflammation-nutritional status.局部晚期肝内胆管癌R0肝切除术后的条件无复发生存率:基于炎症-营养状态的竞争风险分析
Heliyon. 2024 Jul 2;10(13):e33931. doi: 10.1016/j.heliyon.2024.e33931. eCollection 2024 Jul 15.
2
The Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis.R0切除术后局部晚期肝内胆管癌炎症-营养状况与预后的临床关联:来自竞争风险和倾向匹配分析的证据
J Inflamm Res. 2024 May 7;17:2787-2799. doi: 10.2147/JIR.S460103. eCollection 2024.
3
Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study.开发和验证一种新的预后免疫炎症营养评分,用于预测肝内胆管癌根治性切除术后的结局:一项多中心研究。
Front Immunol. 2023 Mar 31;14:1165510. doi: 10.3389/fimmu.2023.1165510. eCollection 2023.
4
Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.纤维蛋白原/白蛋白比值指数是肝内胆管癌患者手术后无复发生存的独立预测因子。
World J Surg Oncol. 2021 Jul 20;19(1):218. doi: 10.1186/s12957-021-02330-2.
5
Construction and validation of a novel prognostic model for intrahepatic cholangiocarcinoma based on a combined scoring system of systemic immune-inflammation index and albumin-bilirubin: a multicenter study.基于全身免疫炎症指数和白蛋白-胆红素联合评分系统构建及验证肝内胆管癌新型预后模型:一项多中心研究
Front Oncol. 2023 Sep 28;13:1239375. doi: 10.3389/fonc.2023.1239375. eCollection 2023.
6
Prediction Efficacy of Prognostic Nutritional Index and Albumin-Bilirubin Grade in Patients With Intrahepatic Cholangiocarcinoma After Radical Resection: A Multi-Institutional Analysis of 535 Patients.预后营养指数和白蛋白-胆红素分级对肝内胆管癌根治性切除术后患者的预测效能:一项对535例患者的多机构分析
Front Oncol. 2021 Dec 10;11:769696. doi: 10.3389/fonc.2021.769696. eCollection 2021.
7
Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma.预测 I 期肝内胆管细胞癌切除术后复发的风险。
J Gastrointest Surg. 2024 Jan;28(1):18-25. doi: 10.1016/j.gassur.2023.10.002.
8
A novel preoperative inflammation score system established for postoperative prognosis predicting of intrahepatic cholangiocarcinoma.一种新型术前炎症评分系统,用于预测肝内胆管癌的术后预后。
BMC Cancer. 2023 Feb 24;23(1):188. doi: 10.1186/s12885-023-10668-x.
9
Prognostic value of preoperative geriatric nutritional risk index in intrahepatic cholangiocarcinoma after hepatectomy: a single‑center retrospective cohort study.术前老年营养风险指数对肝切除术后肝内胆管癌的预后价值:单中心回顾性队列研究。
Langenbecks Arch Surg. 2024 Jan 25;409(1):47. doi: 10.1007/s00423-023-03221-8.
10
Construction and validation of a novel tumor morphology immune inflammatory nutritional score (TIIN score) for intrahepatic cholangiocarcinoma: a multicenter study.构建和验证一种新型的肝内胆管癌肿瘤形态免疫炎症营养评分(TIIN 评分):一项多中心研究。
BMC Cancer. 2024 May 23;24(1):630. doi: 10.1186/s12885-024-12375-7.

本文引用的文献

1
Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer.结合经典和新型中性粒细胞相关生物标志物以识别非小细胞肺癌。
Cancers (Basel). 2024 Jan 25;16(3):513. doi: 10.3390/cancers16030513.
2
Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery.术后肝转移乳腺癌患者白蛋白-胆红素评分的评估
Heliyon. 2023 Oct 30;9(11):e21772. doi: 10.1016/j.heliyon.2023.e21772. eCollection 2023 Nov.
3
Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
基线白蛋白-胆红素分级可预测肝癌患者regorafenib 治疗的反应和结局:系统评价和荟萃分析。
BMC Cancer. 2023 Oct 19;23(1):1006. doi: 10.1186/s12885-023-11488-9.
4
Trials using composite outcomes neglect the presence of competing risks: a methodological survey of cardiovascular studies.使用复合结局的试验忽略了竞争风险的存在:心血管研究的方法学调查。
J Clin Epidemiol. 2023 Aug;160:1-13. doi: 10.1016/j.jclinepi.2023.05.015. Epub 2023 May 27.
5
Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.手术切缘宽度对肝内胆管细胞癌切除术后生存率的影响:系统评价和荟萃分析。
BMJ Open. 2023 May 8;13(5):e067222. doi: 10.1136/bmjopen-2022-067222.
6
Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review.局部进展期肝内胆管细胞癌的治疗:叙述性综述。
Chin Clin Oncol. 2023 Apr;12(2):15. doi: 10.21037/cco-22-115. Epub 2023 Mar 30.
7
A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer.一种用于监测非转移性三阴性乳腺癌实时预后的新型条件生存列线图。
Front Endocrinol (Lausanne). 2023 Feb 24;14:1119105. doi: 10.3389/fendo.2023.1119105. eCollection 2023.
8
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.晚期肾细胞癌免疫治疗的预后和预测生物标志物。
Nat Rev Urol. 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0. Epub 2022 Nov 21.
9
Preoperative Serum Markers and Risk Classification in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study.肝内胆管癌的术前血清标志物与风险分类:一项多中心回顾性研究
Cancers (Basel). 2022 Nov 7;14(21):5459. doi: 10.3390/cancers14215459.
10
Preoperative albumin-bilirubin score as a prognostic indicator in patients with stage III colon cancer.术前白蛋白-胆红素评分作为 III 期结肠癌患者的预后指标。
Sci Rep. 2022 Sep 1;12(1):14910. doi: 10.1038/s41598-022-19329-8.